FDA approves Zurnai, a nalmefene hydrochloride auto-injector, for opioid overdose emergency treatment.

The FDA has approved Zurnai, the first nalmefene hydrochloride auto-injector, for emergency treatment of known or suspected opioid overdose in adults and pediatric patients aged 12 and older. The single-dose, pre-filled auto-injector is available by prescription only and can reverse respiratory depression, sedation, and low blood pressure caused by opioid overdose if administered quickly. The FDA aims to increase options like nalmefene and naloxone to reduce opioid overdoses and their fatalities, with opioid overdose deaths exceeding 107,000 in 2023 primarily due to synthetic opioids like illicit fentanyl.

August 07, 2024
9 Articles

Further Reading